Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.
Rodríguez
J A
JA
Heart Transplant Program, Hospital Juan Canalejo, La Coruña, Spain.
Crespo-Leiro
M G
MG
Paniagua
M J
MJ
Cuenca
J J
JJ
Hermida
L F
LF
Juffé
A
A
Castro-Beiras
A
A
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000453:epidemiology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D002784:Cholesterol